Pregabalin
Product Images NDC 45865-107

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 45865-107). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Medsource Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Pregabalin Capsules 75 mg (Pdp 107)

Pregabalin Capsules 75 mg (Pdp 107)
REGABALNCAPSUES is a generic version of Lyrica, consisting of 30 capsules each containing 75mg of Pregabalin. The drug is manufactured by ScieGen PHARM. INC. and may cause dizziness. It is recommended to take the capsules as directed by a physician and not to transfer the drug to anyone other than the patient for whom it was prescribed. The product is identified by HDC: 45885010730 MFR NDC: 50228-0352-90.*
FDA Label Image

Figure 1 (Pregabalin Fig01)

Figure 1 (Pregabalin Fig01)
The text does not provide a useful description as it contains only scattered numbers and symbols.*
FDA Label Image

Figure 2 (Pregabalin Fig02)

Figure 2 (Pregabalin Fig02)
The available text does not provide a useful description. It seems to be a table or chart with some numerical values related to pain improvement, medication dosages, and time frames, but it lacks context and clear labels.*
FDA Label Image

Figure 3 (Pregabalin Fig03)

Figure 3 (Pregabalin Fig03)
The text contains data points related to the effectiveness of different medications in improving pain in patients. It includes the percentage of patients who experienced improvement as well as the dosages and frequency of administration for three different medications - Pregatalin 300, Pregabain 160, and Pregabalin 75. It also includes a chart showing the percentage of improvement in pain from a baseline.*
FDA Label Image

Figure 4 (Pregabalin Fig04)

Figure 4 (Pregabalin Fig04)
FDA Label Image

Figure 5 (Pregabalin Fig05)

Figure 5 (Pregabalin Fig05)
This appears to be a table showing the dosages of drugs administered to patients and the percentage of improvement in pain from baseline after treatment. "Fregabalin" was given at 100mg three times a day, "Pregataiin" was given at 80mg three times a day, and a "Placebo" was given. The table shows that 38 out of the total number of patients improved, but it is not clear what that total number is. The percentage of improvement in pain ranges from 0.8 to 100, with most patients showing an improvement in the 20-30% range.*
FDA Label Image

Figure 6 (Pregabalin Fig06)

Figure 6 (Pregabalin Fig06)
This appears to be a table with text related to different studies and dosages of a medication. It is not possible to derive any actionable insight from the limited information provided.*
FDA Label Image

Figure 7 (Pregabalin Fig07)

Figure 7 (Pregabalin Fig07)
FDA Label Image

Figure 9 (Pregabalin Fig08)

Figure 9 (Pregabalin Fig08)
This graph shows the percentage improvement in pain from baseline for patients taking Pregabalin at daily doses of 300mg and 450mg versus a placebo. The x-axis shows the range of improvement from 20 to 280 percent and the y-axis shows the percentage of patients improved.*
FDA Label Image

Figure 10 (Pregabalin Fig09)

Figure 10 (Pregabalin Fig09)
This text represents a chart showing the percentage of subjects without LTR, with estimated values ranging from 0% to 100%, along with two treatment options (Progabain and Placebo) displayed on the X-axis. The chart also indicates the time period in days (ranging from 0 to 180) on the Y-axis.*
FDA Label Image

Figure 11 (Pregabalin Fig10)

Figure 11 (Pregabalin Fig10)
FDA Label Image

Figure 12 (Pregabalin Fig11)

Figure 12 (Pregabalin Fig11)
The text shows a graph representing the percent improvement of subjects from baseline to Week 16 BOCF in a study involving Pregabalin and Placebo. The x-axis shows the increments of 10 from 210 to 270, and the y-axis shows the percentage improvement from 0 to 100. The study resulted in 100% improvement, indicating a positive outcome, although it is not clear which treatment (Pregabalin or Placebo) was responsible for the improvement.*
FDA Label Image

Cockcroft And Gault Equation (Pregabalin Formula)

Cockcroft And Gault Equation (Pregabalin Formula)
This text appears to be a formula for calculating creatinine clearance (CLCT) based on a person's age, weight, and serum creatinine levels. However, the has introduced some errors into the text, making it difficult to interpret clearly. In the first part of the formula, it seems to indicate that one should subtract a person's age in years from 140, and then multiply that value by their weight in kilograms. For female patients, the resulting value is then multiplied by 0.85. The second part of the formula appears to involve multiplying 72 by the person's serum creatinine level in mg/dL. However, due to the errors introduced by the , it is difficult to provide a more detailed or accurate description of this text.*
FDA Label Image

Chemical Structure (Pregabalin Str)

Chemical Structure (Pregabalin Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.